|
Detection &
Screening
(Prostate Cancer)
The purpose of screening for cancer is
to detect the cancer at its earliest stages, before any symptoms have
developed. Some men, however, will experience symptoms that might indicate
the presence of prostate cancer. Because these symptoms can also indicate
the presence of other diseases or disorders, these men will undergo a more
thorough work-up. Typically, men whose prostate cancer is detected through
screening are found to have very early-stage disease that can be treated
most effectively.
Screening for prostate cancer can be performed quickly and easily in a
physician’s office using two tests: the PSA (prostate-specific antigen)
blood test, and the digital rectal exam (DRE).
The PSA Blood Test
PSA is a protein produced by the prostate and released in very small amounts
into the bloodstream. When there’s a problem with the prostate, such as when
prostate cancer develops and grows, more and more PSA is released, until it
reaches a level where it can be easily detected in the blood.
During a PSA test, a small amount of blood is drawn from the arm, and the
level of PSA is measured. PSA levels under 4 ng/mL are usually considered
"normal," results over 10 ng/mL are usually considered "high," and results
between 4 and 10 ng/mL are usually considered "intermediate."
However, PSA can also be elevated if other prostate problems are present,
such as BPH or prostatitis, and some men with prostate cancer have "low"
levels of PSA. This is why both the PSA and DRE are used to detect the
presence of disease.
The Digital Rectal Exam
During a DRE, the physician inserts a gloved, lubricated finger into the
rectum and examines the prostate for any irregularities in size, shape, and
texture. Often, the DRE can be used by urologists to help distinguish
between prostate cancer and non-cancerous conditions such as BPH.
Should I Be Screened?
The American Cancer Society recommends that both the PSA and DRE should be
offered annually, beginning at age 50, to men who have at least a 10-year
life expectancy. Men at high risk, such as African American men and men with
a strong family history of one or more first-degree relatives diagnosed at
an early age, should begin testing at age 45. |
|